Cargando cotizaciones...
Previsión
No hay datos de analistas disponibles para esta empresa.
Noticias Ir al feed de noticias
Abbott plans acquisition of Exact Sciences and strengthens cancer diagnostics business
Abbott will acquire Exact Sciences for billions to expand its cancer diagnostics offering. The stock is little changed in premarket trading, even though the acquisition puts the company in the spotlight. » Más en finanzen.net
Abbott disappoints with Q3 numbers, stock worst performer in S&P 500
Abbott increased revenue in the third quarter by nearly 7% to 11.37 billion USD, slightly missing analysts' expectation of 11.39 billion USD. Adjusted earnings per share of 1.30 USD met expectations, and organic revenue growth was 5.5%. The full-year guidance for organic revenue growth was reaffirmed at 7.5–8.0% and the EPS range was narrowed to 5.12–5.18 USD; the stock fell about 3% after the release and finished at the bottom of the S&P 500. » Más en deraktionaer.de
USC Trojans need to close games as Matt Leinart warns Lincoln Riley is on the hot seat
Matt Leinart says USC must improve from last season by winning more than eight games and learning to finish close contests, noting five one-possession losses and that Lincoln Riley is on the hot seat entering 2025. The Trojans return QB Jayden Maiava and face a tough Big Ten slate including Ohio State, Penn State, Oregon, Michigan and Notre Dame, with Leinart saying improvement rather than a playoff berth is the clearest measure of success. Off the field, Leinart discusses his partnership with Abbott’s Ensure Max Protein and his involvement in pickleball with the New Jersey Fives. » Más en forbes.com
Datos financieros de la empresa
| (EUR) | junio de 2026 | YoY |
|---|---|---|
| Ingresos | 46,33 mil | 158,94 % |
| Beneficio bruto | 878,81 | 102,93 % |
| Beneficio neto | -164,4 mil | 42,56 % |
| EBITDA | -136,88 mil | 48,49 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 72,67 mil € |
Número de acciones | 101,29 M |
Máximo/mínimo de 52 semanas | 0,0706 € - 0,000717 € |
| Dividendos | No |
Beta | 0,32 |
Ratio P/E | -2,56 |
Ratio PEG | 0,11 |
Ratio P/B | 4,25 |
Ratio P/S | 29,46 |
Perfil de la empresa
Avricore Health Inc. opera en el sector de datos de salud y tecnologías de diagnóstico en el punto de atención en Canadá. Ofrece HealthTab, una plataforma de pruebas en el punto de atención con precisión de laboratorio para farmacias. La empresa mantiene alianzas estratégicas con Shoppers Drug Mart y Abbott. Anteriormente se llamaba Vanc Pharmaceuticals Inc. y cambió su nombre a Avricore Health Inc. en octubre de 2018. Avricore Health Inc. fue fundada en 1996 y tiene su sede en Vancouver, Canadá.
| Nombre | AVRICORE HEALTH INC. |
| CEO | Rodger Seccombe |
| Sede | Vancouver,
bc Canadá |
| Sitio web | |
| Sector | Materiales |
| Industria | Productos químicos |
| Salida a bolsa | 19/06/2009 |
| Empleados | 26 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
Tsxv | AVCR.V |
Pnk | AVCRF |
Frankfurt | 8VP1.F |